Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.48 |
| ▸ | CCND3 | P30281 | 2/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.46 |
| ▸ | CCNK | O75909 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | CBFB | Q13951 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | LYN | P07948 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3134638 | 0.99 | CYP1A1 (0.47) | CYP1A1CYP1A2CYP1B1CCND3CDK6 | |
| SCHEMBL3138726 | 0.90 | CCNA2 (0.43) | CCND3CDK6CCNKCDK9TYK2 | |
| SCHEMBL3128560 | 0.89 | CCNA2 (0.44) | CCND3CDK6TYK2EGFRMETAP1 | |
| Hydrochloric Acid SCHEMBL3147026 | 0.89 | CCNA2 (0.42) | CCND3CDK6CCNKCDK9TYK2 | |
| Hydrochloric Acid SCHEMBL3143181 | 0.88 | CCNA2 (0.44) | CCND3CDK6TYK2EGFRMETAP1 | |
| SCHEMBL3137902 | 0.87 | CDK6 (0.49) | CCND3CDK6CCNKCDK9EGFR | |
| SCHEMBL3136909 | 0.86 | CDK4 (0.42) | CCND3CDK6CCNKCDK9EGFR | |
| Hydrochloric Acid SCHEMBL3158986 | 0.86 | CDK6 (0.48) | CCND3CDK6CCNKCDK9EGFR | |
| SCHEMBL5256909 | 0.82 | KARS1 (0.47) | CCND3CDK6CCNKCDK9LYN | |
| SCHEMBL6367675 | 0.81 | CYP1A1 (0.70) | CYP1A1CYP1A2CYP1B1ARNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742935-B1 | POLYCYCLIC PYRAZINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN INC (US) | 2010-02-24 | — | — | EP | claimed |
| US-7642354-B2 | Use treating nervous system disorders, as neuroprotectants, gastrointestinal disorders, cardiovascular disorders; e.g. 2-(5-phenylpyridin-2-ylamino)-6-pyridin-2-ylpyrimidine | ICAGEN, INC. (US) | 2010-01-05 | — | — | US | claimed |
| EP-1742935-B1 | POLYCYCLIC PYRAZINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN INC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-7642354-B2 | Use treating nervous system disorders, as neuroprotectants, gastrointestinal disorders, cardiovascular disorders; e.g. 2-(5-phenylpyridin-2-ylamino)-6-pyridin-2-ylpyrimidine | ICAGEN, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20050239800-A1 | Polycyclic pyrazines as potassium ion channel modulators | ICAGEN, INC. (US) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239800-A1 | Polycyclic pyrazines as potassium ion channel modulators | KCNJ2, KCNH2, KCNJ1 | CYP1A1 3465/4885CYP1A2 3165/4885CYP1B1 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.